Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.07 +0.2%	$8.79	$7.35 ▼ $13.70	$2.43B	0.11	490,472 shs	229,923 shs
KNSA Kiniksa Pharmaceuticals International	$33.49 0.0%	$30.31	$17.82 ▼ $34.55	$2.48B	0.14	555,267 shs	316,932 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.61	N/A	N/A
TARS Tarsus Pharmaceuticals	$58.58 +0.7%	$45.57	$25.82 ▼ $58.95	$2.46B	0.79	698,270 shs	374,275 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+0.25%	-4.96%	-17.18%	-30.48%	-30.90%
KNSA Kiniksa Pharmaceuticals International	-0.59%	-0.24%	+10.31%	+22.13%	+27.04%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	+0.59%	+2.83%	+44.89%	+35.44%	+118.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	2.3542 of 5 stars	3.3	4.0	0.0	0.0	1.5	0.0	1.3
KNSA Kiniksa Pharmaceuticals International	2.4144 of 5 stars	2.5	3.0	0.0	0.0	2.9	3.3	0.6
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	1.7857 of 5 stars	2.5	1.0	0.0	0.0	3.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.50	Moderate Buy	$14.00	73.48% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	22.92% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	13.80% Upside

Current Analyst Ratings Breakdown

Latest SVA, KNSA, ALVO, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALVO Alvotech	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	4.95	N/A	N/A	($0.57) per share	-14.16
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.86	N/A	N/A	$6.68 per share	5.01
SVA Sinovac Biotech	$448.27M	1.44	$0.17 per share	38.95	$120.83 per share	0.05
TARS Tarsus Pharmaceuticals	$182.95M	13.52	N/A	N/A	$7.88 per share	7.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.23	35.09	40.35	N/A	11.26%	-38.36%	9.28%	11/12/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	837.46	133.96	N/A	0.90%	1.05%	0.80%	11/4/2025 (Estimated)
SVA Sinovac Biotech	-$99.92M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	11/12/2025 (Estimated)

Latest SVA, KNSA, ALVO, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALVO Alvotech	-$0.26	$0.14	+$0.40	$0.14	$120.51 million	$116.02 million
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.82	1.27
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
SVA Sinovac Biotech	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
SVA Sinovac Biotech	N/A
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
KNSA Kiniksa Pharmaceuticals International	53.48%
SVA Sinovac Biotech	12.79%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
KNSA Kiniksa Pharmaceuticals International	220	74.11 million	34.48 million	Optionable
SVA Sinovac Biotech	3,261	99.64 million	86.89 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable

SVA, KNSA, ALVO, and TARS Headlines

Recent News About These Companies

Jump Financial LLC Takes $2.51 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

August 29 at 5:19 AM | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

August 27 at 5:00 PM | globenewswire.com

16,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Acquired by Quantbot Technologies LP

August 27 at 4:12 AM | marketbeat.com

3 Biotech Catalysts Present Major Opportunity (TARS)

...

August 25, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Aberdeen Group plc

August 24, 2025 | marketbeat.com

Nuveen LLC Purchases New Shares in Tarsus Pharmaceuticals, Inc. $TARS

August 24, 2025 | marketbeat.com

Vanguard Group Inc. Increases Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

August 24, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Atika Capital Management LLC

August 23, 2025 | marketbeat.com

Russell Investments Group Ltd. Acquires 132,450 Shares of Tarsus Pharmaceuticals, Inc. $TARS

August 23, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Invesco Ltd.

August 20, 2025 | marketbeat.com

Lord Abbett & CO. LLC Acquires 51,714 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 16, 2025 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 6,000 Shares of Stock

August 15, 2025 | marketbeat.com

Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.

August 15, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $300,000.00 in Stock

August 14, 2025 | insidertrades.com

Informed Momentum Co LLC Decreases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 14, 2025 | marketbeat.com

Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87

August 12, 2025 | msn.com

Blair William & Co. IL Sells 15,814 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 12, 2025 | marketbeat.com

Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

August 11, 2025 | marketbeat.com

Brokers Offer Predictions for TARS Q3 Earnings

August 11, 2025 | marketbeat.com

Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report

August 9, 2025 | finance.yahoo.com

FY2027 Earnings Forecast for TARS Issued By HC Wainwright

August 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA, KNSA, ALVO, and TARS Company Descriptions

Alvotech NASDAQ:ALVO

$8.07 +0.02 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$8.07 0.00 (0.00%)

As of 04:10 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.49 -0.01 (-0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$33.50 +0.01 (+0.03%)

As of 06:42 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Tarsus Pharmaceuticals NASDAQ:TARS

$58.58 +0.42 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$58.58 +0.01 (+0.01%)

As of 07:58 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time